ESR1 and breast carcinoma: Although several prognostic criteria have already been introduced to assist management after curative surgery for early breast cancer, the need for molecular markers has always been strongly suggested to discriminate individual variability and thus predict relapse or survival in patients with a similar clinical status, Estrogen, acting through predominantly ER), has a significant detrimental impact during its pathogenesis [24].